Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $23.00 Average Price Target from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $29.80.

Several research firms have commented on CRVS. Barclays raised their price objective on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday. HC Wainwright increased their price target on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday. Oppenheimer raised their price target on Corvus Pharmaceuticals from $15.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday. Jefferies Financial Group lifted their price objective on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wall Street Zen raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in Corvus Pharmaceuticals in the third quarter worth approximately $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $49,000. Russell Investments Group Ltd. bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth $49,000. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth $52,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth $54,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $25.10 on Wednesday. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -47.36 and a beta of 0.70. The firm has a 50-day moving average of $9.21 and a two-hundred day moving average of $7.12. Corvus Pharmaceuticals has a 1 year low of $2.54 and a 1 year high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Tuesday, November 4th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Research analysts expect that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.